| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 09/28/2000 | DE19910102A1 Proteinkonjugate, Verfahren, Vektoren, Proteine und DNA zu deren Herstellung, deren Verwendung, sowie Arzneimittel und Impfstoffe mit einem Gehalt derselben Protein conjugates, methods, vectors, proteins, and DNA for their preparation, their use, as well as drugs and vaccines containing the same |
| 09/28/2000 | CA2855415A1 Phenylalanine derivatives |
| 09/28/2000 | CA2371990A1 Use of stabilised oligonucleotides for preparing a medicine with antitumour activity |
| 09/28/2000 | CA2367266A1 Gel-microemulsion formulations |
| 09/28/2000 | CA2367093A1 Propofol formulation containing tris |
| 09/28/2000 | CA2367040A1 Pharmaceutical compositions comprising a pyrimidine derivative and cyclodextrin |
| 09/28/2000 | CA2366998A1 Quinazoline formulations and therapeutic use thereof |
| 09/28/2000 | CA2366908A1 Vaccine composition |
| 09/28/2000 | CA2366869A1 Use of trehalose for stabilising a liquid vaccine |
| 09/28/2000 | CA2366859A1 Method for improving the stability of stored and/or used light-sensitive therapeutic systems or components thereof |
| 09/28/2000 | CA2366845A1 Composition for medicated chewing gums, process for manufacturing the same and tablets so obtained |
| 09/28/2000 | CA2366669A1 Cell-culture and polymer constructs |
| 09/28/2000 | CA2366650A1 Oral low dose butyrate compositions |
| 09/28/2000 | CA2366613A1 Particle based vaccine composition |
| 09/28/2000 | CA2365121A1 Antibodies specific for cyp1b1 |
| 09/28/2000 | CA2353556A1 Methods for inhibiting the formation of endoleaks associated with endovascular repair of abdominal aortic aneurysms |
| 09/27/2000 | EP1038891A2 Water soluble or water dispersable polymeric salts |
| 09/27/2000 | EP1038534A2 Process for the preparation of a conjugate of pharmacologically active substances |
| 09/27/2000 | EP1038528A1 Pentosan polysulfate containing medicament and implant for treating fibrosis |
| 09/27/2000 | EP1038527A1 Process for producing granulates containing riboflavine |
| 09/27/2000 | EP1038525A1 Stable drug composition |
| 09/27/2000 | EP1038521A1 Flexible gelatin free encapsulation material useful for pharmaceuticals, paint balls and other formulations |
| 09/27/2000 | EP1038180A1 Beta(1-3)-glucan diagnostic assays |
| 09/27/2000 | EP1038016A2 Needle-free injection of formulated nucleic acid molecules |
| 09/27/2000 | EP1037969A1 Fibrinogen-converting enzyme hybrids |
| 09/27/2000 | EP1037938A1 Hyperbranched polymers or dendrimers having a particular group, preparation method and compositions containing same |
| 09/27/2000 | EP1037929A1 Non-aqueous, heterogeneous polymerization process and reaction product obtained thereby |
| 09/27/2000 | EP1037927A2 Heterodimeric fusion proteins useful for targeted immune therapy and general immune stimulation |
| 09/27/2000 | EP1037917A1 Recombinant nodavirus compositions and methods |
| 09/27/2000 | EP1037903A1 Peptide-based gemini compounds |
| 09/27/2000 | EP1037670A2 Agent for gene therapy of tumor, neurodegenerative, cardiovascular and autoimmune diseases |
| 09/27/2000 | EP1037668A1 Transfection particles |
| 09/27/2000 | EP1037667A1 Pharmaceutical hydrogel formulations, drug delivery devices and methods |
| 09/27/2000 | EP1037666A1 Method for enhancing the absorption and transport of lipid soluble compounds using structured glycerides |
| 09/27/2000 | EP1037659A1 Fibrinolytic inhibitor for sealant |
| 09/27/2000 | EP1037657A1 Alpha-interferon-polymer-conjugates having enhanced biological activity and methods of preparing the same |
| 09/27/2000 | EP1037649A1 Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents |
| 09/27/2000 | EP1037647A1 Medicinal plant dry extracts |
| 09/27/2000 | EP1037642A1 Modified polysaccharides exhibiting altered biological recognition |
| 09/27/2000 | EP1037634A1 Novel administration form comprising an acid-labile active compound |
| 09/27/2000 | EP1037615A2 Compositions and methods for treatment of attention deficit disorder and attention deficit/hyperactivity disorder with methylphenidate |
| 09/27/2000 | EP1037614A2 A double capsule for the administration of active principles in multiple therapies |
| 09/27/2000 | EP1037611A1 Biodegradable mixed polymeric micelles for gene delivery |
| 09/27/2000 | EP1037610A1 Liposomal camptothecin formulations |
| 09/27/2000 | EP1037609A1 Aqueous insecticidal pour-on formulation |
| 09/27/2000 | EP1037607A1 Novel suppository form comprising an acid-labile active compound |
| 09/27/2000 | EP1037604A1 Pharmaceutical aerosol compositions |
| 09/27/2000 | EP1037597A1 Use of hyperbranched polymers and dendrimers comprising a particular group as film-forming agent, film-forming compositions comprising same and use particularly in cosmetics and pharmaceutics |
| 09/27/2000 | EP1037587A1 Site-specific preparation of polyethylene glycol-grf conjugates |
| 09/27/2000 | EP1005351A4 An aqueous metal bicarbonate solution and method of use |
| 09/27/2000 | EP0764170B1 Branched synthetic peptide conjugate |
| 09/27/2000 | CN1268062A Modified polypeptides with high activity and reduced allergenicity |
| 09/27/2000 | CN1268057A Cross-linked polysaccharide drug carrier |
| 09/27/2000 | CN1268055A Pharmaceutical suspension comprising nevirapine hemihydrate |
| 09/27/2000 | CN1268054A Combination therapy comprising amlodipine and a statin compound |
| 09/27/2000 | CN1268052A Therapeutic combinations comprising amlodipin and atorvastatin |
| 09/27/2000 | CN1268051A Clear, injectable formulation of an anesthetic compound |
| 09/27/2000 | CN1268050A Pharmaceutical composition for combination of piperidinoalkanol-decongestant |
| 09/27/2000 | CN1267550A Commonly used buffer salt tablet and its preparation |
| 09/26/2000 | US6124358 Pharmaceutical composition containing rhein or diacerhein with improved bioavailability |
| 09/26/2000 | US6124322 An aqueous thalidomide solution comprising a pure enantiomer of thalidomide dissolved in an isotonic glucose solution |
| 09/26/2000 | US6124310 Enediyne compounds |
| 09/26/2000 | US6124274 Use of ascorbyl 2'-phosphates for stabilizing vitamin A and/or vitamin A derivatives in cosmetic and pharmaceutical preparations |
| 09/26/2000 | US6124273 Sustained release wound healing agents |
| 09/26/2000 | US6124271 Method and conjugate for treating H. pylori infection |
| 09/26/2000 | US6124270 Use of a cationic amphipathic compound as a transfection agent, vaccine additive or drug |
| 09/26/2000 | US6124268 Natural antioxidant compositions, method for obtaining same and cosmetic, pharmaceutical and nutritional formulations thereof |
| 09/26/2000 | US6124261 Non-aqueous polar aprotic peptide formulations |
| 09/26/2000 | US6124258 Heat resistant, sterilized carbonic acid-iron-casein complex lacking astringent taste; antianemia agents |
| 09/26/2000 | US6123974 Hydroxy-methyl-hexanones as flavoring agents |
| 09/26/2000 | US6123965 Methods and compositions for enhancing the bioadhesive properties of polymers |
| 09/26/2000 | US6123963 Coating or binder for pharmaceutical preparation comprising a polyurethane consisting of polyol(s), polyetherpolyol(s), a diamine having ionic group, and a polyisocyanate, in given proportions, without further additives; storage stability |
| 09/26/2000 | US6123962 Process for producing stabilized pharmaceutical composition |
| 09/26/2000 | US6123959 Phospholipids, and competitive inhibitor(s) including arbutin of an enzyme for the synthesis of melanin, tyrosinase and non-competitive inhibitor(s) of tyrosinase selected from specified substituted 4-oxo-chromene compounds |
| 09/26/2000 | US6123953 Synergistic topical mixture of a 1,2-alkanediol of given formula and a clathrate glyceryl poly(meth)acrylate gel of given viscosity comprising 20-90% glycerin, 10-80% water and 0.1-5% weight of poly(meth)acrylate; preventing mastitis |
| 09/26/2000 | US6123936 Methods and compositions for the dry powder formulation of interferons |
| 09/26/2000 | US6123922 Resilient deformable microballoons for echographic imaging |
| 09/26/2000 | CA2181990C Rapidly dissolving oral dosage form |
| 09/26/2000 | CA2126244C Suspension aerosol formulations |
| 09/26/2000 | CA1341102C Tetra-aza macrocycles and metal complexes thereof |
| 09/24/2000 | CA2298236A1 Flexible gelatin free encapsulation material useful for pharmaceuticals, paint balls and other formulations |
| 09/21/2000 | WO2000055210A1 Method for the reductive amination of polysaccharides |
| 09/21/2000 | WO2000055208A2 Chimeric toxins |
| 09/21/2000 | WO2000055149A1 Dimeric compounds and as inhibitors of neuraminidase |
| 09/21/2000 | WO2000055133A1 1-acyl-7-nitroindoline derivatives, their preparation and their use as photocleavable precursors |
| 09/21/2000 | WO2000055072A2 Aerosol metering valve |
| 09/21/2000 | WO2000054812A1 Improved composition for oral administration |
| 09/21/2000 | WO2000054811A1 Medicinal compositions |
| 09/21/2000 | WO2000054807A1 Ligand-bonded complex |
| 09/21/2000 | WO2000054802A2 Method of expressing antigens on the surface of antigen presenting cells by photochemical internalization |
| 09/21/2000 | WO2000054798A1 Antiviral agent in the form of nose drops |
| 09/21/2000 | WO2000054797A2 Pharmaceutical compositions comprising tgf-beta |
| 09/21/2000 | WO2000054794A1 Wafer delivery system |
| 09/21/2000 | WO2000054789A1 Bacterial membrane fractions with adjuvant effect |
| 09/21/2000 | WO2000054786A1 Methods and compositions for tolerizing hosts for long term survival of tissue transplants |
| 09/21/2000 | WO2000054777A1 Controlled release of sildenafil delivered by sublingual or buccal administration |
| 09/21/2000 | WO2000054775A1 Stable pharmaceutical application form for paroxetin anhydrate |
| 09/21/2000 | WO2000054774A1 Apomorphine and sildenafil composition |
| 09/21/2000 | WO2000054762A2 Use of cross linked polysaccharides for the inhibition of angiogenesis |
| 09/21/2000 | WO2000054754A2 Composition comprising isoquercetin and ascorbic acid in a sustained release form |